BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 19245588)

  • 1. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
    Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
    Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
    Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
    Leav I; McNeal JE; Ho SM; Jiang Z
    Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
    Stewart J; Fleshner N; Cole H; Toi A; Sweet J
    J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
    Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
    Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
    Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
    Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
    Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
    Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
    Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
    Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
    Santinelli A; Mazzucchelli R; Barbisan F; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Am J Clin Pathol; 2007 Oct; 128(4):657-66. PubMed ID: 17875519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas.
    Engers R; Ziegler S; Mueller M; Walter A; Willers R; Gabbert HE
    Endocr Relat Cancer; 2007 Jun; 14(2):245-56. PubMed ID: 17639041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
    Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
    Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J
    Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
    Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
    Takahashi S; Suzuki S; Takahashi S; Inaguma S; Asamoto M; Shirai T
    Prostate; 2006 Feb; 66(2):211-7. PubMed ID: 16173032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
    Herawi M; Epstein JI
    Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.